NOTE: You're viewing the Google AMP version of this site. It makes things load fast, but limits the frills you'll see. Click here if you'd prefer to start at our regular home page (it's still mobile friendly!).

Buy Trulieve Cannabis for a big return: Beacon Securities

Expect a catalyst-rich first half of 2019 for Trulieve Cannabis Corp (Trulieve Cannabis Corp Stock Quote, Chart CSE:TRUL), according to analyst Russell Stanley of Beacon Securities, who on Monday launched coverage of TRUL with a “Buy” recommendation and C$28.00 target price, representing a projected return of 93 per cent.

Florida-based cannabis company Trulieve, which began trading on the CSE last September, owns 24 of Florida’s 90 dispensaries, with management stating that it currently has an approximate market share of 60 to 70 per cent. The company is also expanding into California and Massachusetts via acquisitions

Stanley estimates that cannabis companies with an operational focus on the US currently trade at an average multiple discount of 42 per cent relative to their Canada-focused peers, a difference which he attributes to concerns (outdated, in his estimation) connected to cannabis’ federal status in the US. Stanley believes that US regulatory environment should continue to improve, making US companies an attractive option.

“Relative to the vast majority of Canadian operators, we believe US operating companies generally offer investors a much deeper addressable market, more established business models, broader product suites and greater immediate private sector participation throughout the value chain, particularly in distribution and retail,” says Stanley.

Stanley also praises Trulieve’s 44 per cent EBITDA margins, coming from its third quarter 2018 financials, which the analyst calls “otherwise unheard of.”

“We value TRUL using a 20x EV/2020E EBITDA multiple applied to our forecast of $124 million,” he says. “This is in line with the broad peer group average, which we view as conservative considering the company’s dominant position in a major market, and industry leading 44 per cent EBITDA margins. This multiple also represents a 50 per cent discount to the 40x average for the closest peers (companies with C$1-billion-plus market capitalizations), reflecting residual regulatory uncertainty and a modest float.”

The analyst sees a number of upcoming catalysts for TRUL, including: further M&A activity, completion of its California acquisition, additional dispensary openings in Florida (a market which Stanley says is “nowhere near saturation yet”) and progress on the buildout of its Massachusetts acquisition. Other regulatory and legislative catalysts exist at the state and federal levels, as well, Stanley says.

The analyst projects that TRUL will generate Adj. EBITDA in 2019 of $90.7 million on revenue of $208.7 million and Adj. EBITDA in 2020 of $124.3 million on a top line of $281.3 million. (All figures in US dollars unless otherwise noted.)

Related Posts

Share
Tagged with: trul

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Willow Biosciences has a huge upside, says AltaCorp Capital

With sales of cannabinoids expected in two years’ time, Willow Biosciences (Willow Biosciences Stock Quote, Chart, News CSE:WLLW) is on… [Read More]

8 hours ago

Raymond James launches coverage of Organigram with an “Outperform” rating

Moncton, New Brunswick’s Organigram Holdings (Organigram Holdings Stock Quote, Chart, News TSX:OGI) is the manufacturing ‘Beast from the East,’ according… [Read More]

24 hours ago

Former Canopy Growth CEO Bruce Linton says weak pot companies will die

It’s been a rough few months for the cannabis sector but former Canopy Growth co-CEO Bruce Linton thinks that times… [Read More]

24 hours ago

United Technologies is a better buy than Raytheon, this investor says

Regulators are still poring over the details but the merger between Raytheon (Raytheon Stock Quote, Chart, News NYSE:RTN) and United… [Read More]

1 day ago

Burcon Nutrascience is still undervalued, Beacon says

Shares of protein extraction company Burcon Nutrascience (Burcon Nutrascience Stock Quote, Chart, News TSX:BU) have been climbing in recent months,… [Read More]

1 day ago

Chorus Aviation investors need patience, this investor says

Investors looking for more upside this year from Chorus Aviation (Chorus Aviation Stock Quote, Chart, News TSX:CHR) may be disappointed,… [Read More]

2 days ago
NOTE: You're viewing the Google AMP version of this site. It makes things load fast, but limits the frills you'll see. Click here if you'd prefer our non-AMP home page (it's still mobile friendly!).